期刊文献+

高效液相色谱法测定盐酸埃克替尼软膏含量及有关物质 被引量:1

Determination of related substances and content of icotinib hydrochloride cream by HPLC
原文传递
导出
摘要 目的:采用HPLC法测定盐酸埃克替尼乳膏含量及有关物质。方法:含量测定采用Grace C18色谱柱(250 mm×4.6 mm,5μm),流动相为0.02 mol·L-1磷酸二氢钠溶液-乙腈(50∶50),流速为1.0 m L·min-1,检测波长为334 nm。有关物质检测采用Grace C18色谱柱(250 mm×4.6 mm,5μm),0.1 mol·L-1磷酸二氢钠溶液-乙腈(60∶40)为流动相,检测波长为246 nm,流速为1.0 m L·min-1。结果:盐酸埃克替尼在4.01~40.10μg·m L-1范围内具有良好的线性关系(A=51 863C-11 321,r2=0.999 7),重复性良好(RSD=1.46%)。进样精密度、重复性良好。平均回收率为99.15%,RSD值为0.58%。空白辅料不干扰检测,盐酸埃克替尼与相关杂质之间的分离度良好。结论:本方法可以方便、快速、准确地检测盐酸埃克替尼乳膏的含量及其有关物质。 Objective: To develop high performance liquid chromatography( HPLC) methods for the determination of icotinib hydrochloride and its related substances. Methods: Grace C18column( 250 mm × 4. 6 mm,5 μm) was used for the determination of Icotinib Hydrochloride. The mobile phase was 0. 02 mol·L- 1sodium dihydrogen phosphate buffer-acetonitrile( 50∶ 50) with the flow rate set at 1. 0 m L·min- 1. The detection wavelength was 334 nm. Grace C18column( 250 mm × 4. 6 mm,5 μm) was used for detecting the related substances. The mobile phase was 0. 1 mol·L- 1sodium dihydrogen phosphate buffer-acetonitrile( 60∶ 40) with the flow rate set at 1. 0 m L·min- 1. The detection wavelength was 246 nm. Results: The calibration curve of Icotinib Hydrochloride was linear in the range of 4. 01 ~ 40. 10 μg·m L- 1( A = 51 863C- 11 321,r2= 0. 999 7). Repeatability was good( RSD =0. 24%). Icotinib hydrochloride and its related substances were completely separated. Conclusion: The established methods possess the characteristics of specificity,easy operating,accuracy and good reproducibility,and can be employed to determine the content and related substances of icotinib hydrochloride.
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第21期2516-2520,共5页 Chinese Journal of New Drugs
关键词 盐酸埃克替尼乳膏 高效液相色谱法 含量测定 有关物质 icotinib hydrochloride cream HPLC determination related substances
  • 相关文献

参考文献4

二级参考文献17

  • 1邬楠,王爱平,王印祥.表皮生长因子受体酪氨酸激酶抑制剂BPI-2009的抗肿瘤作用及其机制的研究[J].中国临床药理学与治疗学,2005,10(4):456-461. 被引量:7
  • 2张阳,张力,徐菲,王志强,赵洪云,管忠震,徐光川,潘振奎.吉非替尼记名供药计划(EAP)治疗晚期非小细胞肺癌患者的临床研究结果[J].癌症,2006,25(12):1561-1564. 被引量:9
  • 3FDA. Guidance for Industry: Analytical procedures and methods validation, chemistry, manufacturing, and controls documentation (Draft) [S]. 2000. 被引量:1
  • 4ICH Q2A :Test on Validation of Analytical Procedures[S]. 2007. 被引量:1
  • 5ICH Q2B : Validation of Analytical Procedures : Methodology [ S ]. 2007. 被引量:1
  • 6国家食品药品监督管理局.化学药物质量控制分析方法验证技术指导原则[S].2005 被引量:3
  • 7国家食品药品监督管理局.化学药品杂质研究的技术指导原则[S].2005. 被引量:1
  • 8GUAN ZM, CHEN XY, WANG YX, et al. Metabolite identification of new antitumor agent lcotinib in rats using liquid chromatograph/ tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom, 2008,22(14) :2176 -2184. 被引量:1
  • 9LIU DY, ZHANG L, JIANG J, et al. Phase Ⅰ studies of the novel oral EGFR inhibitor, lcotinib, in health male subjects [ C ]. 13^th World Conference on Lung Cancer(WCLC). San Francisco, 2009. 被引量:1
  • 10ZHANG L, JIANG J, LIU DY,et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC :results from a phase Ⅰ/Ⅱ trial (13th World Conference on Lung Cancer(WCLC). San Francisco. 被引量:1

共引文献106

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部